Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.55 |
| ▸ | CCND1 | P24385 | 4/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31257964 | 1.00 | CDK4 (0.55) | CDK4CCND1HTR6L3MBTL1ALDH1A1 | |
| SCHEMBL6087599 | 0.88 | CDK4 (0.50) | CDK4CCND1HTR6KMT2ASIGMAR1 | |
| SCHEMBL31258040 | 0.83 | CDK4 (0.49) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL31258085 | 0.83 | PPARG (0.56) | CDK4CCND1HTR6 | |
| SCHEMBL6087030 | 0.83 | CDK4 (0.49) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL6087034 | 0.83 | PPARG (0.56) | CDK4CCND1HTR6 | |
| SCHEMBL6087283 | 0.83 | CDK4 (0.52) | CDK4CCND1HTR6KMT2ASIGMAR1 | |
| SCHEMBL6192770 | 0.82 | HTR6 (0.49) | CDK4CCND1HTR6SMN1; SMN2KMT2A | |
| SCHEMBL6087045 | 0.82 | CDK4 (0.55) | CDK4CCND1HTR6KMT2ASIGMAR1 | |
| SCHEMBL31257888 | 0.82 | CDK4 (0.55) | CDK4CCND1HTR6KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109020976-B | Pyrimidotriazole-indole-containing compound and preparation method and application thereof | 郑州大学 | 2020-04-17 | — | — | CN | disclosed |
| CN-109020976-A | Pyrimido triazole-Benzazole compounds and its preparation method and application | 郑州大学 | 2018-12-18 | — | — | CN | disclosed |
| CN-1250542-C | 2-(1H-indol-3-yl)-2-oxo-acetamides with antitumor activity | NOVUSPHARMA SPA (IT) | 2006-04-12 | — | — | CN | disclosed |
| US-6987122-B2 | 2-(1H-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2006-01-17 | — | — | US | disclosed |
| EP-1244652-B1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE SRL (IT) | 2005-08-24 | — | — | EP | disclosed |
| US-6753342-B2 | ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT | NOVUSPHARMA S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | NOVUSPHARMA S.P.A. (IT) | 2003-08-21 | — | — | US | disclosed |
| EP-1322646-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2003-07-02 | — | — | EP | disclosed |
| CN-1413205-A | 2- (1H-indol-3-yl) -2-oxo-acetamides with antitumor activity | NOVUSPHARMA SPA (IT) | 2003-04-23 | — | — | CN | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002008225-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | IDO2, IDO1, TXNRD2 | CDK4 570/4885CCND1 265/4885HTR6 2619/4885 |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | IDO1, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CDK4 1693/4885CCND1 1793/4885HTR6 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.